enGene to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

enGene Holdings, a clinical-stage genetic medicines company, announced that their CEO, Jason Hanson, will present a corporate overview at the Jefferies Global Healthcare Conference.

The event will take place in New York City on June 5, 2024, at 12:30 p.m. ET.

enGene's lead program, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

The presentation will be webcast live and archived on the enGene website for 90 days.

Positive

• CEO Jason Hanson will present at the Jefferies Global Healthcare Conference, which can increase visibility and investor interest.
• The lead program, EG-70, is in a pivotal study for NMIBC, indicating progress in clinical development.
• The live webcast and 90-day archive provide extended access for stakeholders and potential investors.

Negative

• There are no financial updates or specific clinical results mentioned, leaving gaps in investor information.
• The pivotal study status of EG-70 could imply that significant hurdles remain before potential market approval and commercial success.
• The PR does not provide any new data or outcomes from the ongoing pivotal study, which might cause uncertainty.

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET.

A live webcast of the presentation can be accessed under the Investors section of the enGene website at www.engene.com/presentations and will be archived there for 90 days.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529566127/en/

Investor

investors@engene.com

Media

media@engene.com

Source: enGene Holdings Inc.

FAQ

When will enGene present at the Jefferies Global Healthcare Conference?

enGene will present on June 5, 2024, at 12:30 p.m. ET.

What is the focus of enGene's lead program EG-70?

EG-70 is focused on BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Where can I access the live webcast of enGene's presentation?

You can access the live webcast under the Investors section of the enGene website at www.engene.com/presentations.

How long will the webcast of enGene's presentation be available?

The webcast will be archived and available for 90 days.